Sources Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (PMC) Application of nutrition interventions with GLP-1 based therapies: a narrative review (PMC) Endocrine Society: Consuming more protein may protect patients taking anti-obesity drug from muscle loss (ENDO 2025) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists (PMC) MedlinePlus: Fiber MedlinePlus: High-fiber foods Mayo Clinic Health System: Assessing protein needs Mayo Clinic: High-protein snacks Therapeutic Benefits and Dietary Restrictions of Fiber Intake (PMC)
For example, semaglutide can be increased up to 2 mg weekly for diabetes (Ozempic), or up to 2.4 mg weekly for weight management (Wegovy)
In Greer, J.P., Foerster, J., Rodgers, G.M., Paraskevas, F., Glader, B., Arber, D.A., Means Jr., R.T
The trial in people with T2D included 281 participants (mean age 56 years, 56% women, mean BMI 35.0 kg/m 2 , mean HbA1c 8.3%) treated with lifestyle only and/or metformin, with similar intervention arms to the obesity trial, albeit retatrutide 0.5 mg rather than 1 mg, and dulaglutide 1.5 mg was an additional comparator [46]
The other factors are less circumscribed